Asthma Exacerbation Management

Initial Treatment Protocol

The American Academy of Allergy, Asthma, and Immunology recommends administering albuterol 2.5-5 mg plus ipratropium 0.5 mg via nebulizer every 20 minutes for 3 doses, combined with oral prednisone 40-60 mg (adults) or 1-2 mg/kg (children, max 60 mg) for acute asthma exacerbations in the emergency department 1, 2
For adults and children ≥12 years, albuterol via MDI is an alternative for mild-moderate exacerbations, with a dose of 4-8 puffs every 20 minutes for 3 doses, and must be used with a valved holding chamber (VHC) 1, 2, 3
Children <12 years should receive albuterol 0.15 mg/kg (minimum 2.5 mg) every 20 minutes for 3 doses via nebulizer, and children <4 years should use a face mask with the VHC for MDI administration 2, 3
Ipratropium bromide can be added to albuterol via nebulizer, with a dose of 0.5 mg for adults and 0.25-0.5 mg for children, every 20 minutes for 3 doses 1, 2

The American Academy of Allergy, Asthma, and Immunology recommends reassessing patients after the initial 3 doses using subjective symptom response, physical examination findings, and FEV₁ or peak expiratory flow measurements 1
Response to treatment is a better predictor of hospitalization need than initial severity, with a recommendation to continue bronchodilator therapy as needed 1, 4
For patients requiring ongoing treatment, albuterol 2.5-10 mg every 1-4 hours as needed, and ipratropium 0.5 mg as needed, can be administered 2, 3

Levalbuterol can be administered as an alternative to albuterol, at half the milligram dose, with a recommended dose of 1.25-2.5 mg every 20 minutes for 3 doses for adults, and 0.075 mg/kg (minimum 1.25 mg) every 20 minutes for 3 doses for children 2, 4
Intravenous magnesium sulfate can be considered for life-threatening exacerbations, with a dose of 2 g over 20 minutes for adults, or 25-75 mg/kg up to 2 g for children 1, 4

The American Academy of Allergy, Asthma, and Immunology recommends avoiding routine use of antibiotics, aggressive hydration in older children and adults, and use of methylxanthines, chest physiotherapy, mucolytics, or sedation 1
Monitoring for beta-agonist toxicity, such as tachycardia, tremor, and hypokalemia, is recommended, especially with high-dose or continuous administration 3, 4

The American Academy of Allergy, Asthma, and Immunology recommends monitoring for signs of impending respiratory failure, including inability to speak in full sentences, altered mental status, intercostal retractions, worsening fatigue despite treatment, and rising PaCO₂ levels 4